- Trials with a EudraCT protocol (91)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
91 result(s) found for: Fusion Inhibitor.
Displaying page 1 of 5.
EudraCT Number: 2017-004246-20 | Sponsor Protocol Number: 20810 | Start Date*: 2018-03-06 | ||||||||||||||||
Sponsor Name:Bayer Consumer Care AG | ||||||||||||||||||
Full Title: A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-1... | ||||||||||||||||||
Medical condition: NTRK fusion cancers previously treated with a TRK inhibitor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IE (Completed) IT (Ongoing) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000769-18 | Sponsor Protocol Number: EFC16295 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-X... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) HU (Completed) NL (Completed) IT (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003582-28 | Sponsor Protocol Number: LOXO-TRK-15002 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) IE (Restarted) ES (Ongoing) PT (Trial now transitioned) FR (Ongoing) DE (Ongoing) SE (Ongoing) BE (Ongoing) CZ (Completed) SK (Completed) NO (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002023-15 | Sponsor Protocol Number: EFC16293 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. (a Sanofi company) | |||||||||||||
Full Title: Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTE... | |||||||||||||
Medical condition: severe hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) BG (Completed) BE (Completed) GR (Completed) HU (Completed) NL (Completed) ES (Completed) Outside EU/EEA IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002215-22 | Sponsor Protocol Number: LTS16294 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the long-term safety and efficacy of intravenous recombinant coagulation factor VIII Fc-von willebrand factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Ongoing) GR (Ongoing) IE (Trial now transitioned) SE (Trial now transitioned) HU (Ongoing) DE (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002463-10 | Sponsor Protocol Number: BLU-667-2303 | Start Date*: 2020-05-28 | ||||||||||||||||
Sponsor Name:Blueprint Medicines Corporation | ||||||||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: RET fusion-positive, Metastatic Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NO (Trial now transitioned) FI (Completed) BE (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) CZ (Prematurely Ended) NL (Ongoing) PT (Trial now transitioned) DK (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003685-33 | Sponsor Protocol Number: HLS01/2006 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO A.O. DI RILIEVO NAZIONALE | |||||||||||||
Full Title: Study of viro-immunological dynamics and T-lymphocyte homeostasis in peripheral blood in the pathogenesisof HIV infection and in the response to antiretroviral therapy. | |||||||||||||
Medical condition: Treatment of HIV-1 infection in INRs patients compared to classical HAART. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003498-16 | Sponsor Protocol Number: LOXO-TRK-15003 | Start Date*: 2017-02-10 | ||||||||||||||||||||||||||
Sponsor Name:Loxo Oncology Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
Medical condition: Central Nervous System Neoplasms and advanced solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Restarted) SE (Trial now transitioned) DK (Trial now transitioned) FR (Ongoing) NL (Trial now transitioned) IE (Trial now transitioned) PL (Ongoing) IT (Ongoing) CZ (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003999-38 | Sponsor Protocol Number: Bay a 0128/11799 | Start Date*: 2006-04-06 | |||||||||||
Sponsor Name:Bayer Pharmaceuticals Corporation | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal ... | |||||||||||||
Medical condition: Elective Spinal Fusion Surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006032-23 | Sponsor Protocol Number: CSL654_3002 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children ... | |||||||||||||
Medical condition: Prophylaxis and treatment of bleeding episodes in previously treated children with congenital FIX deficiency (hemophilia B) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003895-21 | Sponsor Protocol Number: 997HA309 | Start Date*: 2020-11-01 |
Sponsor Name:Biogen MA Inc | ||
Full Title: A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths... | ||
Medical condition: Hemophilia A | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-018477-38 | Sponsor Protocol Number: CSL654_2001 | Start Date*: 2010-11-15 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B. | |||||||||||||
Medical condition: Prophylaxis and treatment of bleeding episodes in subjects with congenital Factor IX (FIX) deficiency (Hemophilia B) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000640-18 | Sponsor Protocol Number: NANT2015-02 | Start Date*: 2018-08-13 |
Sponsor Name:NANT Operations Centre | ||
Full Title: NANT 2015-02: PHASE 1 STUDY OF LORLATANIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA | ||
Medical condition: Relapsed or refractory high risk neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005489-37 | Sponsor Protocol Number: CSL654_3003 | Start Date*: 2014-07-11 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) BG (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003584-53 | Sponsor Protocol Number: Debio1347-201 | Start Date*: 2019-02-05 |
Sponsor Name:Debiopharm International SA | ||
Full Title: A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 | ||
Medical condition: Three cohorts will be included consisting of subjects with biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and all other solid tumor histologies not included in Cohorts 1-2 such as NS... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) GR (Temporarily Halted) AT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DK (Completed) NO (Completed) BG (Completed) FI (Completed) ES (Temporarily Halted) HR (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001029-32 | Sponsor Protocol Number: PBI-200-101 | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:Pyramid Biosciences, Inc. | |||||||||||||
Full Title: A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors | |||||||||||||
Medical condition: One of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002415-28 | Sponsor Protocol Number: CSL654_3001 | Start Date*: 2012-01-19 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000065-73 | Sponsor Protocol Number: Sobi.Elocta-003 | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | |||||||||||||
Full Title: A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Faile... | |||||||||||||
Medical condition: Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction Therapies | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IE (Completed) GB (Completed) BE (Completed) FR (Completed) SE (Completed) SI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012504-13 | Sponsor Protocol Number: A8081005 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP... | |||||||||||||
Medical condition: metastatic non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) FR (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004987-21 | Sponsor Protocol Number: ONO-7579-01 | Start Date*: 2017-09-13 | |||||||||||
Sponsor Name:Ono Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors | |||||||||||||
Medical condition: Advanced solid tumors and Neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.